Key points from article :
Founded in 2014, France-based Eligo Bioscience has received $20m Series A funding.
Aims is to treat a number of diseases using the human microbiome.
Eligo’s biological nanobots (aka eligobots) are made from DNA and protein.
Able to deliver a customised therapeutic payload to specific types of bacteria.
Nanobots can either kill the bacteria or transiently turn them into drug producers.
